Charles River Laboratories International (CRL) EBITDA Margin (2009 - 2025)

Charles River Laboratories International (CRL) has reported EBITDA Margin for 17 consecutive years, with 28.51% the latest figure, recorded in Q4 2025.

• In Q4 2025, EBITDA Margin fell 1178.0% year-over-year to 28.51%; the TTM figure through Dec 2025 stood at 0.63% (down 499.0% YoY), while the FY2025 annual figure was 0.63%, down 499.0% from the prior year.
• EBITDA Margin came in at 28.51% for Q4 2025 at Charles River Laboratories International, down from 13.32% in the prior quarter.
• The five-year high for EBITDA Margin was 19.26% in Q2 2022, with the low at 28.51% in Q4 2025.
• Average EBITDA Margin over 5 years is 10.81%, with a median of 14.84% recorded in 2022.
• Across the five-year window, EBITDA Margin jumped 422 bps in 2022 and plunged 2984 bps in 2024, its largest moves.
• Year by year, EBITDA Margin stood at 19.09% in 2021, then dropped by 22 bps to 14.89% in 2022, then fell by 12 bps to 13.12% in 2023, then sank by 228 bps to 16.73% in 2024, then plunged by 70 bps to 28.51% in 2025.
• According to Business Quant data, EBITDA Margin over the past three periods registered 28.51%, 13.32%, and 9.7% for Q4 2025, Q3 2025, and Q2 2025 respectively.